|  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Metabolic syndrome component**  | **All prostate cancers** | **Race interaction** |  | **Low-grade PC** | **Race interaction** |  | **High-grade PC** | **Race interaction** |
| **OR** | **95% CI** | **P** |  |  | **OR** | **95% CI** | **P** |  |  | **OR** | **95% CI** | **P** |  |
| Univariable |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| Obesity | 0.76 | 0.59-0.98 | 0.032 |  |  | 0.72 | 0.55-0.95 | 0.018 |  |  | 0.88 | 0.60-1.29 | 0.51 |  |
| Hypertriglyceridemia | 0.88 | 0.69-1.14 | 0.34 |  |  | 0.87 | 0.66-1.14 | 0.30 |  |  | 0.93 | 0.64-1.36 | 0.72 |  |
| Dyslipidemia | 0.74 | 0.58-0.95 | 0.019 |  |  | 0.68 | 0.52-0.89 | 0.005 |  |  | 0.94 | 0.65-11.36 | 0.73 |  |
| Hypertension | 1.05 | 0.75-1.47 | 0.79 |  |  | 0.89 | 0.62-1.27 | 0.53 |  |  | 1.88 | 1.01-3.50 | 0.045 |  |
| Diabetes | 0.98 | 0.76-1.28 | 0.90 |  |  | 0.97 | 0.73-1.28 | 0.81 |  |  | 1.03 | 0.70-1.53 | 0.87 |  |
|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| Multivariable\* |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| Obesity | 1.14 | 0.84-1.54 | 0.40 | 0.87 |  | 1.08 | 0.79-1.47 | 0.63 | 0.83 |  | 1.47 | 0.92-2.33 | 0.11 | 0.95 |
| Hypertriglyceridemia | 1.02 | 0.76-1.39 | 0.88 | 0.26 |  | 1.00 | 0.73-1.36 | 0.98 | 0.20 |  | 1.15 | 0.72-1.82 | 0.57 | 0.99 |
| Dyslipidemia | 0.99 | 0.73-1.33 | 0.94 | 0.38 |  | 0.92 | 0.68-1.26 | 0.62 | 0.52 |  | 1.32 | 0.83-2.08 | 0.24 | 0.32 |
| Hypertension | 0.94 | 0.63-1.40 | 0.74 | 0.18 |  | 0.86 | 0.57-1.30 | 0.48 | 0.12 |  | 1.51 | 0.75-3.04 | 0.25 | 0.56 |
| Diabetes | 1.10 | 0.81-1.51 | 0.54 | 0.91 |  | 1.07 | 0.77-1.47 | 0.69 | 0.89 |  | 1.25 | 0.78-2.02 | 0.35 | 0.84 |

**Supplementary Table 5. Univariable and multivariable OR and 95% CIs for the association between metabolic syndrome components and risk of prostate cancer**

\*Adjusted for age, year, race, log transformed PSA, DRE, and log transformed TRUS.